Roubaix Capital LLC Invests $2.28 Million in Bio-Rad Laboratories, Inc. $BIO

Roubaix Capital LLC purchased a new stake in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) in the third quarter, according to its most recent disclosure with the SEC. The firm purchased 8,112 shares of the medical research company’s stock, valued at approximately $2,275,000.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BIO. Quent Capital LLC purchased a new position in Bio-Rad Laboratories in the 3rd quarter valued at about $25,000. Farther Finance Advisors LLC increased its position in shares of Bio-Rad Laboratories by 52.9% during the third quarter. Farther Finance Advisors LLC now owns 104 shares of the medical research company’s stock worth $29,000 after acquiring an additional 36 shares during the last quarter. Geneos Wealth Management Inc. lifted its stake in shares of Bio-Rad Laboratories by 115.2% in the second quarter. Geneos Wealth Management Inc. now owns 142 shares of the medical research company’s stock worth $34,000 after acquiring an additional 76 shares in the last quarter. CWM LLC lifted its stake in shares of Bio-Rad Laboratories by 82.0% in the third quarter. CWM LLC now owns 202 shares of the medical research company’s stock worth $57,000 after acquiring an additional 91 shares in the last quarter. Finally, UMB Bank n.a. boosted its holdings in Bio-Rad Laboratories by 24.0% in the third quarter. UMB Bank n.a. now owns 207 shares of the medical research company’s stock valued at $58,000 after purchasing an additional 40 shares during the last quarter. Hedge funds and other institutional investors own 65.24% of the company’s stock.

Bio-Rad Laboratories Trading Up 0.5%

Shares of NYSE BIO opened at $279.78 on Tuesday. The company has a quick ratio of 4.19, a current ratio of 5.62 and a debt-to-equity ratio of 0.16. The stock’s 50 day moving average price is $297.65 and its two-hundred day moving average price is $301.49. Bio-Rad Laboratories, Inc. has a 52-week low of $211.43 and a 52-week high of $343.12. The stock has a market capitalization of $7.55 billion, a P/E ratio of 10.02 and a beta of 1.18.

Bio-Rad Laboratories (NYSE:BIO) last issued its earnings results on Thursday, February 12th. The medical research company reported $2.51 EPS for the quarter, missing the consensus estimate of $2.57 by ($0.06). The firm had revenue of $693.20 million during the quarter, compared to analyst estimates of $694.64 million. Bio-Rad Laboratories had a return on equity of 3.86% and a net margin of 29.42%.Bio-Rad Laboratories’s revenue was up 3.9% compared to the same quarter last year. During the same quarter in the previous year, the business posted $2.90 EPS. On average, analysts anticipate that Bio-Rad Laboratories, Inc. will post 10.81 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

BIO has been the topic of several analyst reports. Weiss Ratings restated a “sell (d-)” rating on shares of Bio-Rad Laboratories in a report on Monday, December 29th. Wall Street Zen downgraded shares of Bio-Rad Laboratories from a “buy” rating to a “hold” rating in a research report on Saturday, February 14th. Three investment analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat.com, the company presently has an average rating of “Hold” and a consensus price target of $358.50.

Bio-Rad Laboratories Profile

Bio-Rad Laboratories, Inc is a global provider of life science research and clinical diagnostic products. The company operates through two primary business segments: Life Science and Clinical Diagnostics. Within the Life Science segment, Bio-Rad offers instruments, reagents and consumables for protein analysis, cell biology, gene expression and other molecular biology applications. The Clinical Diagnostics segment supplies quality control products, blood-typing reagents and instruments, and molecular diagnostic assays used in blood screening, infectious disease testing and routine clinical laboratories.

Founded in 1952 by David and Alice Schwartz and headquartered in Hercules, California, Bio-Rad has grown its footprint across the Americas, Europe, Asia-Pacific and other regions.